A Phase 1b Proof-of-concept Trial Exploring the Effects of FE 999322 and FE 999324 in Adults With Mild to Moderate Ulcerative Colitis
To explore the safety of FE 999322 (microbiota suspension) and FE 999324 (microbiota capsule) versus placebo in subjects with active mild to moderate ulcerative colitis (UC).
- EligibilityCriteria: Inclusion Criteria:  Subject aged ≥18 at screening Established diagnosis of ulcerative colitis by standard clinical, endoscopic and histological criteria, for more than 3 months at screening  Exclusion Criteria:  Active disease or history of Crohn's disease Active disease or history of irritable bowel syndrome (IBS) or any other chronic intestinal disease apart from UC Active gastrointestinal infection. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult